Aprotinin

• 

  Subject Areas on Research

  • A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. 
  • Activated clotting time measurements and aprotinin studies. 
  • Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. 
  • Antibody formation after drug administration during cardiac surgery: parameters for aprotinin use. 
  • Antifibrinolytic Therapy for Cardiac Surgery: An Update. 
  • Antithrombin deficiency in special clinical syndromes--Part II: cardiovascular surgery. 
  • Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. 
  • Aprotinin improves functional outcome but not cerebral infarct size in an experimental model of stroke during cardiopulmonary bypass. 
  • Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. 
  • Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: yes. 
  • Aprotinin use during cardiac surgery: recent alterations and effects on blood product utilization. 
  • Aprotinin versus tranexamic acid: the controversy continues. 
  • Aprotinin's effect on blood product transfusion in off-pump bilateral lung transplantation. 
  • Aprotinin: a pharmacologic overview. 
  • Aprotinin: safe and effective only with the full-dose regimen. 
  • Bleeding and management of coagulopathy. 
  • Case 1-2008. One institution's decreasing use of aprotinin during cardiac surgery in 2006. 
  • Case 3--1999. Intraoperative coronary thrombosis in association with low-dose aprotinin therapy. 
  • Case 4-2007. Aprotinin-induced cardiovascular collapse after a negative test dose in a patient scheduled for repeat mitral valve surgery. 
  • Coagulopathy and inflammation in neonatal heart surgery: mechanisms and strategies. 
  • Comparative analysis of antifibrinolytic medications in pediatric heart surgery. 
  • Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons. 
  • Coronary artery bypass grafting after aprotinin: are we doing better? 
  • Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials. 
  • Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial. 
  • Determinants of backbone dynamics in native BPTI: cooperative influence of the 14-38 disulfide and the Tyr35 side-chain. 
  • Efficacy and safety of aprotinin in cardiac surgery. 
  • Enhanced protein flexibility caused by a destabilizing amino acid replacement in BPTI. 
  • Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. 
  • Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes. 
  • Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. 
  • Hemostatic agents and their safety. 
  • Hemostatic agents. 
  • High-dose aprotinin effectively reduces blood loss during on-pump coronary artery bypass grafting with bivalirudin anticoagulation. 
  • Homogeneous NMR spectra in inhomogeneous fields. 
  • Identification of a residue critical for maintaining the functional conformation of BPTI. 
  • Increased anticoagulation during cardiopulmonary bypass by aprotinin. 
  • Inflammatory response to cardiopulmonary bypass. 
  • Invited commentary. 
  • Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen. 
  • Managing clotting: a North American perspective. 
  • Massive transfusion coagulopathy. 
  • Novel pharmacologic approaches to reduce bleeding. 
  • Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation. 
  • Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. 
  • Pharmacologic methods to reduce perioperative bleeding. 
  • Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. 
  • Predicting and preventing adverse neurologic outcomes with cardiac surgery. 
  • Risk of anaphylaxis from aprotinin re-exposure during LVAD removal and heart transplantation. 
  • Safety of aprotinin in congenital heart operations: results from a large multicenter database. 
  • Safety of aprotinin in heparinized and nonheparinized patients. 
  • The association of renal dysfunction and the use of aprotinin in patients undergoing congenital cardiac surgery requiring cardiopulmonary bypass. 
  • The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation. 
  • The effect of aprotinin on outcome after coronary-artery bypass grafting. 
  • The effects of aprotinin on outcome from cerebral ischemia in the rat. 
  • The inflammatory response to cardiopulmonary bypass. 
  • The role of aprotinin in a blood-conservation program. 
  • Thrombomodulin increases the rate of thrombin inhibition by BPTI. 
  • ε-Aminocaproic acid and clinical value in cardiac anesthesia. 
• 

  Keywords of People

  • Milano, Carmelo Alessio, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Surgery, Cardiovascular and Thoracic Surgery